Strand Therapeutics Inc., a Cambridge, Mass.-based biotechnology company specialized in developing gene therapies powered by synthetic biology, completed a $6m seed funding round.
The round was led by Playground Global with participation from Alexandria Venture Investments, ANRI, and a group of private investors.
The company will use the proceeds to make key hires at its headquarters in Cambridge, Massachusetts, grow its pipeline of engineered gene therapies, and further develop its synthetic biology platform.
Led by Jacob Becraft, Ph.D., co-founder and CEO, Strand Therapeutics is building a platform based on technology developed by biological engineers at MIT including scientific co-founders, Professor Ron Weiss, Ph.D., a pioneer of the field of synthetic biology, and Professor Darrell J. Irvine, Ph.D., a researcher of materials for immune-engineering, who sought to apply synthetic biology to the emerging field of mRNA therapeutics.
It is a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program.